Background: Childhood interstitial and diffuse lung diseases are a collection of rare disorders with significant associated morbidity. Only a small subset of these diseases have precise diagnostic or therapeutic options identified to date.
Methods: Whole-exome sequencing in a family identified a candidate pathogenic variant predicted to be causing fibrotic lung and liver disease in a child. Digital spatial mRNA profiling of clinical lung biopsies was done to identify aberrant signaling pathways. ELISA confirmed low circulating protein levels in the patient.
Findings: We identified homozygosity of the p.Cys139Arg loss-of-function progranulin (GRN) variant and an alveolar macrophage transcriptomic signature consistent with tumor necrosis factor alpha (TNF-α) pathway activation. This motivated treatment with anti-TNF monoclonal antibodies, resulting in dramatic improvement of the patient's lung and liver disease.
Conclusions: These findings demonstrate the clinical utility of convergent multiomics in the evaluation and implementation of precision therapeutics in rare diseases.
Funding: This work was supported by a grant from the Chan Zuckerberg Initiative Patient-Partnered Collaboration for single-cell analysis of rare inflammatory pediatric disease, the Corkin Family Fund for Research, and in part by cooperative agreement U01TR002623 from the National Center for Advancing Translational Sciences/NIH and the PrecisionLink Project at Boston Children's Hospital.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2025.100607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasound-guided interstitial photothermal therapy generates improved treatment responses in a 9464D model of neuroblastoma.
Bioeng Transl Med
March 2025
George Washington Cancer Center, School of Medicine and Health Sciences George Washington University Washington, DC USA.
We describe the use of ultrasound image guidance to improve treatment outcomes when administering interstitial photothermal therapy (I-PTT), an experimental cancer treatment modality. I-PTT is a promising thermal therapy for tumors using intratumorally injected nanoparticle-based photothermal agents activated by an interstitially placed laser diffuser. We hypothesized that ultrasound-based image guidance yields improved tumor treatment outcomes in terms of tumor regression and survival by improving the accuracy of the placement of the laser fiber and nanoparticles within a tumor and facilitating more precise PTT delivery.
View Article and Find Full Text PDFDIAGNOSTIC EVALUATION AND CLINICAL FINDINGS IN CHILDREN WITH PERSISTENT TACHYPNEA OF INFANCY/NEUROENDOCRINE CELL HYPERPLASIA OF INFANCY: A EUROPEAN MULTICENTER RETROSPECTIVE STUDY.
Chest
March 2025
AP-HP, Sorbonne Université, Pediatric Pulmonology Department and Reference Center for Rare Lung Disease RespiRare, Armand Trousseau Hospital, Paris, France.
Background: Persistent tachypnea of infancy (PTI)/neuroendocrine cell hyperplasia of infancy (NEHI) is a form of childhood interstitial lung disease (chILD) that predominantly affects young children. Although it is one of the most common chILDs, there is no unified diagnostic approach specific to this condition.
Research Question: Is there a difference in the clinical presentation and the diagnostic approach in PTI/NEHI patients between the European countries?
Study Design And Methods: This was a European multicenter, retrospective, observational study.
Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency.
ERJ Open Res
March 2025
Service de Pneumologie A, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
https://bit.ly/3TMWKK9.
View Article and Find Full Text PDFBi-allelic LAMP3 variants in childhood interstitial lung disease: a surfactant-related disease.
EBioMedicine
February 2025
Sorbonne University, Inserm UMR_S933 Laboratory of Childhood Genetic Diseases, Armand Trousseau Hospital, Paris, France; Assistance Publique Hôpitaux de Paris, Pediatric Pulmonology Department, Reference Centre for Rare Lung Diseases (RespiRare), Armand Trousseau Hospital, Paris, France.
Background: LAMP3 encodes a lysosomal membrane protein associated with lamellar bodies and has recently been proposed as a candidate gene for childhood interstitial lung diseases (chILD). Here, we identified two LAMP3 variants in a proband with chILD and performed functional validation of these variants as well as the previously reported variants to demonstrate the role of LAMP3 in pathology.
Methods: LAMP3 variants were identified by exome sequencing.
A progranulin variant causing childhood interstitial lung disease responsive to anti-TNF-α biologic therapy.
Med
February 2025
Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Background: Childhood interstitial and diffuse lung diseases are a collection of rare disorders with significant associated morbidity. Only a small subset of these diseases have precise diagnostic or therapeutic options identified to date.
Methods: Whole-exome sequencing in a family identified a candidate pathogenic variant predicted to be causing fibrotic lung and liver disease in a child.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!